Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
144
-
Total 13F shares, excl. options
-
13.3M
-
Shares change
-
+331K
-
Total reported value, excl. options
-
$444M
-
Value change
-
+$17.8M
-
Put/Call ratio
-
0
-
Number of buys
-
79
-
Number of sells
-
-51
-
Price
-
$33.50
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q4 2016
160 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q4 2016.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 144 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.3M shares
of 27.8M outstanding shares and own 47.79% of the company stock.
Largest 10 shareholders include BlackRock Fund Advisors (1.45M shares), Krensavage Asset Management, LLC (1.06M shares), GREAT POINT PARTNERS LLC (828K shares), VANGUARD GROUP INC (739K shares), RENAISSANCE TECHNOLOGIES LLC (575K shares), ACADIAN ASSET MANAGEMENT LLC (569K shares), STATE STREET CORP (568K shares), GRANAHAN INVESTMENT MANAGEMENT INC/MA (496K shares), FIRST MANHATTAN CO (485K shares), and BlackRock Institutional Trust Company, N.A. (459K shares).
This table shows the top 144 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.